Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. This milestone advances the company’s chemistry, manufacturing and controls (CMC) strategy as it moves toward IND-enabling studies and planning for first-in-human clinical evaluation.
The program will focus on optimizing synthetic processes, improving yield and reproducibility, and scaling production of key intermediates required for downstream manufacturing and formulation. The effort is conducted in collaboration with Dalton Pharma Services and aims to establish a robust, scalable manufacturing process capable of supporting continued preclinical development, regulatory readiness, and future clinical supply requirements.
This development is significant for the oncology field as it brings ONC010 closer to clinical testing. ONC010 targets solid tumors, a major area of unmet medical need. By ensuring a reliable and scalable manufacturing process, Onco-Innovations is addressing a critical hurdle in drug development—translating laboratory discoveries into treatments that can be produced consistently for clinical trials and, ultimately, for patients. The collaboration with Dalton Pharma Services, a contract development and manufacturing organization, leverages expertise in pharmaceutical manufacturing to accelerate this transition.
For investors and the biotechnology industry, this announcement signals that Onco-Innovations is progressing its pipeline with a focus on regulatory preparedness. The CMC strategy is a core component of any investigational new drug (IND) application, and advancing this work reduces risk and timelines for subsequent clinical phases. The company’s exclusive worldwide license to patented technology targeting solid tumors further underscores its commitment to innovative cancer treatments.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. More information can be found at https://oncoinnovations.com/.
The full press release is available at https://nnw.fm/kfFWv.
